



WHO IMPLEMENTATION TOOL FOR PRE-EXPOSURE PROPHYLAXIS (PrEP) OF HIV INFECTION

JULY 2017



WHO/HIV/2017.31

© **World Health Organization 2017**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO Implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. Module 11: PrEP users. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Layout by L'IV Com Sàrl, Villars-sous-Yens, Switzerland.

Cover photos: ©prepster.info; © JohnRaeNYC; © Innovation: Africa

Contents

INTRODUCTION	2
THE PrEP USERS MODULE	4
QUESTIONS THAT PEOPLE RAISE WHEN CONSIDERING PrEP	4
What is PrEP?	4
How well does PrEP work?	4
Who should consider using PrEP?	4
Who cannot use PrEP?	5
What are different ways to stay free of HIV?	5
Where can I get PrEP?	6
Do I have to use condoms while I am taking PrEP?	6
QUESTIONS THAT PEOPLE RAISE WHILE USING PrEP	6
How do I store my PrEP medication?	6
When and how do I take PrEP?	6
How can I remember to take PrEP?	7
What if I miss a dose?	7
What if I have side-effects?	7
What other service may be available for me when I take PrEP?	7
What if I want to become pregnant while taking PrEP?	8
Can I keep taking PrEP while pregnant and breastfeeding?	8
What can I say to others about my PrEP use?	8
When and how can I stop PrEP?	8

Introduction

Following the WHO recommendation in September 2015 that “oral pre-exposure prophylaxis (PrEP) should be offered as an additional prevention choice for people at substantial risk of HIV infection as part of combination HIV prevention approaches”, partners in countries expressed the need for practical advice on how to consider the introduction of PrEP and start implementation. In response, WHO has developed this series of modules to support the implementation of PrEP among a range of populations in different settings.

Although there is growing acknowledgement of PrEP’s potential as an additional HIV prevention option and countries are beginning to consider how PrEP might be most effectively implemented, there has been limited experience with providing PrEP outside research and demonstration projects in low- and middle-income countries. Consequently, there is often uncertainty around many implementation issues. The modules in this tool provide initial suggestions for the introduction and implementation of PrEP based on currently available evidence and experience. However, it is recognized that this evidence may evolve following wider PrEP use; therefore, it is likely that this tool will require regular updating.

PrEP should not replace or compete with effective and well-established HIV prevention interventions, such as comprehensive condom programming for sex workers and men who have sex with men and harm reduction for people who inject drugs. Many people who could benefit most from PrEP belong to key population groups that may face legal and social barriers to accessing health services. This needs to be considered when developing PrEP services. Although the public health approach underpins the WHO guidance on PrEP, the decision to use PrEP should always be made by the individual concerned.

Target audience and scope of tool

This PrEP tool contains modules for a range of stakeholders to support them in the consideration, planning, introduction and implementation of oral PrEP. The modules can be used on their own or in combination. In addition, there is a module for individuals interested in or already taking PrEP. (See Summary of modules below.)

This tool is the product of collaboration between many experts, community organizations and networks, implementers, researchers and partners from all regions. The information presented is aligned with WHO’s 2016 consolidated guidelines on the use of antiretroviral drugs for HIV treatment and prevention.

All modules make reference to the evidence-based 2015 WHO recommendation on PrEP. They do not make any new recommendations on PrEP, focusing instead on suggested implementation approaches.

Guiding principles

It is important to adopt a public health, human rights and people-centred approach when offering PrEP to those at substantial risk of HIV. Similar to other HIV prevention and treatment interventions, a human rights-based approach gives priority to issues concerning universal health coverage, gender equality and health-related rights including accessibility, availability, acceptability and quality of PrEP services.

SUMMARY OF MODULES



Module 1: Clinical. This module is for clinicians, including physicians, nurses and clinical officers. It gives an overview of how to provide PrEP safely and effectively, including: screening for substantial risk of HIV; testing for HIV before initiating someone on PrEP and how to follow up PrEP users and offer counselling on adherence.



Module 2: Community educators and advocates. Community educators and advocates are needed to increase awareness about PrEP in their communities. This module provides information on PrEP that should be considered in community-led activities that aim to increase knowledge about PrEP and generate demand and access.



Module 3: Counsellors. This module is for staff who counsel people as they consider PrEP or start taking PrEP and support them in coping with side-effects and adherence strategies. Those who counsel PrEP users may be lay, peer or professional counsellors and healthcare workers, including nurses, clinical officers and doctors.



Module 4: Leaders. This module aims to inform and update leaders and decision-makers about PrEP. It provides information on the benefits and limitations of PrEP so that they can consider how PrEP could be effectively implemented in their own settings. It also contains a series of frequently asked questions about PrEP.



Module 5: Monitoring and evaluation. This module is for people responsible for monitoring PrEP programmes at the national and site levels. It provides information on how to monitor PrEP for safety and effectiveness, suggesting core and additional indicators for site-level, national and global reporting.



Module 6: Pharmacists. This module is for pharmacists and people working in pharmacies. It provides information on the medicines used in PrEP, including on storage conditions. It gives suggestions for how pharmacists and pharmacy staff can monitor PrEP adherence and support PrEP users to take their medication regularly.



Module 7: Regulatory officials. This module is for national authorities in charge of authorizing the manufacturing, importation, marketing and/or control of antiretroviral medicines used for HIV prevention. It provides information on the safety and efficacy of PrEP medicines.



Module 8: Site planning. This module is for people involved in organizing PrEP services at specific sites. It outlines the steps to be taken in planning a PrEP service and gives suggestions for personnel, infrastructure and commodities that could be considered when implementing PrEP.



Module 9: Strategic planning. As WHO recommends offering PrEP to people at substantial HIV risk, this module offers public health guidance for policy-makers on how to prioritize services, in order to reach those who could benefit most from PrEP, and in which settings PrEP services could be most cost-effective.



Module 10: Testing providers. This module is for people who provide testing services at PrEP sites and laboratories. It offers guidance in selecting testing services, including screening of individuals before PrEP is initiated and monitoring while they are taking PrEP. Information is provided on HIV testing, creatinine, HBV and HCV, pregnancy and STIs.



Module 11: PrEP users. This module provides information for people who are interested in taking PrEP to reduce their risk of acquiring HIV and people who are already taking PrEP – to support them in their choice and use of PrEP. This module gives ideas for countries and organizations implementing PrEP to help them develop their own tools.



Module 12: Adolescents and young adults. This module is for people who are interested in providing PrEP services to older adolescents and young adults who are at substantial risk for HIV. It provides information on: factors that influence HIV susceptibility among young people; clinical considerations for safety and continuation on PrEP; ways to improve access and service utilization; and inclusive monitoring approaches to improve the recording and reporting of data on young people.

ANNEXES

Review of evidence. A wide range of evidence including the following two systematic reviews informed the 2015 WHO recommendation on PrEP for people at substantial risk of HIV infection: (i) Fonner VA et al. *Oral tenofovir-based HIV pre-exposure prophylaxis (PrEP) for all populations: a systematic review and meta-analysis of effectiveness, safety, behavioural and reproductive health outcomes*; (ii) Koechlin FM et al. *Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature*.

Annotated Internet resources. This list highlights some of the web-based resources on PrEP currently available together with the stakeholder groups they are catering to. WHO will continue to provide updates on new resources.

The PrEP Users module

This module is for people who are considering starting PrEP or who are currently using PrEP. Countries and PrEP services can adapt its contents to provide information about PrEP availability and PrEP services that are more specific to their setting. For example, links to specific locations can be added to the section titled "Where can I get PrEP?", and links to local community-based and other resources can be added to the list of annotated Internet resources in the annex.

The World Health Organization recommends that PrEP should be offered to people who are at substantial risk of acquiring HIV infection.

WHO Recommendation for PrEP

The World Health Organization recommends that PrEP containing tenofovir disoproxil fumarate (TDF) should be offered as an additional prevention choice for people at substantial risk of HIV infection as part of combination prevention approaches (*strong recommendation; high-quality evidence*).

Questions that people raise when considering PrEP

What is PrEP?

Pre-exposure prophylaxis (PrEP) is when people take an HIV medication to reduce their chance of getting infected while they are at risk of acquiring HIV. WHO currently recommends the use of PrEP taken daily for both men and women who are at substantial risk of acquiring HIV.

How well does PrEP work?

- PrEP does not provide 100% protection, but it is highly effective and provides a great deal of protection against HIV. In some recent studies, PrEP has been shown to reduce the risk of HIV infection during sex by over 90% when used consistently.
- PrEP is more effective for those who take PrEP regularly (that is, who are adherent) than for those who often miss their daily dose.
- Taking PrEP *every day* is recommended because daily use of PrEP is effective, safe and the most convenient approach. Daily PrEP use provides the highest amount of medication in the blood and body tissues and, thus, the highest level of protection. If you take PrEP daily, you may still be protected, even if you miss a dose once in a while.
- Time is needed to build up protective levels of the medicine in the blood and other tissues. Additional HIV prevention should be taken for the first seven days when starting PrEP. Ways to lower risk during this period include: adopting safer sexual practices, such as not having vaginal or anal intercourse, or using condoms. It is suggested that PrEP should be continued for 28 days after the last potential exposure to HIV.

Who should consider using PrEP?

PrEP is for people in situations and times in their lives when they may have a high risk of HIV infection. PrEP may offer you a way to help manage your risk of getting HIV. ***If you think that you are at high risk of HIV infection***, and you live in a place or in a community with a high HIV prevalence, there are many reasons why PrEP could be something for you to consider. For example:

- You are not using condoms all the time with all sexual partners.
- You are having or have had sex with more than one sexual partner in a six-month period.
- You have a sexual partner who has other sexual partners and may be likely to have or be at high risk of HIV infection.

- You are having unprotected sex with a person who injects drugs and shares injection equipment with others.
- You inject drugs and share injecting equipment.
- You have sex when drinking alcohol and/or taking recreational drugs.
- You have been told that you have a sexually transmitted infection, such as gonorrhoea, syphilis, chancroid or herpes.
- You have a sex partner who was recently told that he or she has a sexually transmitted infection, including HIV.
- You are having unprotected sex with someone who has HIV and who is not on antiretroviral therapy, or who is on antiretroviral therapy but has not achieved suppression of viral load to undetectable levels.
- You and your sexual partner do not discuss your concerns about HIV, or your partner does not know his/her HIV status.

Most of these risks will be greater in places where HIV prevalence is high.

In addition, members of the following populations may want to learn more about whether PrEP is a good choice for them:

- men and transgender people who have sex with men
- sex workers, especially if not able to use condoms with every sex act
- people with a sexual partner who has HIV (that is, being in a serodiscordant couple) and who is not on antiretroviral therapy and virally suppressed
- people, including adolescent girls and young women, who live in areas with a high HIV incidence
- people who inject drugs.

Who cannot use PrEP?

- People who already have HIV should not take PrEP. Instead, they should be offered antiretroviral therapy.
- People with kidney disease should not use PrEP containing tenofovir.

What are different ways to stay free of HIV?

There are many ways to stay free of HIV infection. You should choose what best suits your own needs and personal situation. You may combine different ways of staying free of HIV, and you can change which strategies you use over time. Here are some of the other things you can do to protect yourself.

- **Male and female condoms (with lubricants)** are effective when they are used consistently, with all sexual partners. Condoms also protect against other sexually transmitted infections and pregnancy.
- If you have a partner who has HIV, **treatment** of his or her infection with antiretroviral therapy can nearly eliminate the risk of transmission. For your partner's HIV treatment to protect you from HIV infection, your partner should have a viral load test that shows that their HIV has been suppressed to "undetectable" levels. If you have doubts about your partner's adherence to HIV treatment or the result of his or her viral load test, it is best to protect yourself in additional ways.
- **Post-exposure prophylaxis (or PEP)** is antiretroviral medication that can be taken after you have an exposure to body fluids containing HIV. For PEP to work well, you must start PEP as soon as possible after the exposure and no later than 72 hours after exposure. PEP should be continued for 28 days after the exposure.
- Being in a sexual relationship with **only one partner** can be helpful for preventing HIV infection if both partners have been tested and disclosed their HIV status to each other, and if they have agreed to have no other sexual partners. This applies when both partners are HIV-negative, or when one partner is negative and the other has HIV and is on antiretroviral therapy and virally suppressed. Such relationships are safer if you and your partner can discuss your agreements and expectations often. It is not reliable to simply assume, without any discussion, that your partner is not having sex with anyone else.
- If you inject drugs, it is recommended to use **new or sterile injection equipment, whenever possible**. This will prevent HIV transmission as well as other transmissible blood-borne infections such as hepatitis B and C.

Where can I get PrEP?

- PrEP is relatively new. Although an increasing number of clinics are offering it, it may be difficult to find a clinic that offers it in your area and in some countries PrEP is not currently available.
- Ask at your local clinic. If they do not know about PrEP, you can show them this publication. You can also ask them to help you find out where you can get it.
- Ask your friends about PrEP and if they know where to get it.

Do I have to use condoms while I am taking PrEP?

- PrEP does not require the use of condoms to be effective. However, condoms provide additional protection against HIV and protect you from other sexually transmitted infections and unplanned pregnancies:
 - PrEP does not prevent sexually transmitted infections, such as syphilis, gonorrhoea, chlamydia and hepatitis. Condoms, however, do provide protection against these other infections as well as against HIV, and so they protect your overall sexual health.
 - PrEP does not prevent pregnancy. When used consistently, condoms prevent pregnancy. There are many other ways to prevent pregnancy, including oral contraceptive pills and injectable hormones, implants, intrauterine devices and diaphragms. PrEP does not interfere with any contraceptive method.

Questions that people raise while using PrEP

How do I store my PrEP medication?

- There are usually 30 pills in each bottle (30 days of PrEP). Store the bottle at room temperature (not in a refrigerator and not in a hot place such as a car).
- Keep the pills in the bottle with the desiccant (the small bag or round plastic capsule that comes with the bottle to keep the medicine dry). If you wish, you can remove pills from their bottle and place them in a seven-day pill box, since this is only for a short time.

When and how do I take PrEP?

- WHO recommends that you take PrEP once a day every day. Daily use is safe and convenient and it provides the best protection against HIV.
- PrEP can be taken at any time during the day and at different times on different days.
- It is helpful to link taking PrEP with something that you do every day.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26344

